Grupo para la caracterización molecular de las neoplasias hematológicas
Hôpital Saint-Louis
París, FranciaPublicaciones en colaboración con investigadores/as de Hôpital Saint-Louis (5)
2023
-
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267
2022
-
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nature Medicine, Vol. 28, Núm. 2, pp. 325-332
2019
-
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 5, pp. 421-431
2016
-
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma
Haematologica
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557